^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) + benmelstobart (APL-502) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preliminary results of TQB2450 (PD-L1 blockade) plus anlotinib combined with oxaliplatin and capecitabine in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, multicenter phase II clinical trial.
Published date:
01/17/2023
Excerpt:
Pts with HER2-negative unresectable locally advanced or metastatic G/GEJ adenocarcinoma...In consequence, the preliminary ORR was 75.0% (95%CI: 50.9%~91.3%), DCR was 95.0% (95%CI: 75.1%~99.9%)….Preliminary results suggested that TQB2450 plus anlotinib combined with CAPEOX in first-line setting for advanced G/GEJ adenocarcinoma exhibited encouraging efficacy and manageable adverse events.
Secondary therapy:
CAPOX
DOI:
10.1200/JCO.2023.41.3_suppl.367
Trial ID:
